Comparative Pharmacology
Head-to-head clinical analysis: LASMIDITAN versus ZAVZPRET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASMIDITAN versus ZAVZPRET.
LASMIDITAN vs ZAVZPRET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lasmiditan is a selective serotonin 5-HT1F receptor agonist. It acts centrally to inhibit trigeminal nerve activation and release of neuropeptides such as calcitonin gene-related peptide (CGRP), thereby aborting migraine pain without vasoconstriction.
ZAVZPRET (zavegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It blocks CGRP-mediated vasodilation and nociceptive signaling in the trigeminovascular system, thereby aborting migraine attacks.
50 mg or 100 mg orally as a single dose; may repeat after at least 2 hours if needed, not to exceed 200 mg in 24 hours.
10 mg administered orally once daily. The dose may be reduced to 7.5 mg or 5 mg if needed based on tolerance.
None Documented
None Documented
Terminal elimination half-life: 5.7 hours (range 4-7 hours); supports BID dosing for acute treatment.
Terminal elimination half-life approximately 20-30 hours in adults, allowing for once-daily dosing.
Primarily hepatic metabolism (CYP3A4); <1% excreted unchanged in urine; ~50% fecal elimination mainly as metabolites.
Primarily renal excretion as unchanged drug (approximately 60-70% of administered dose) with biliary/fecal elimination accounting for approximately 20-30%.
Category C
Category C
CGRP Receptor Antagonist
CGRP Receptor Antagonist